The presence of a caregiver is associated with patient outcomes in patients with Parkinson's disease and atypical parkinsonisms

2020 ◽  
Vol 78 ◽  
pp. 61-65 ◽  
Author(s):  
Lindsay Penny Prizer ◽  
Benzi M. Kluger ◽  
Stefan Sillau ◽  
Maya Katz ◽  
Nicholas B. Galifianakis ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Patient Outcomes ◽  
Atypical Parkinsonisms

scholarly journals Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson’s Disease and Atypical Parkinsonisms

2020 ◽  
Vol 14 ◽  
Author(s):  
Samanta Mazzetti ◽  
Mara De Leonardis ◽  
Gloria Gagliardi ◽  
Alessandra Maria Calogero ◽  
Milo Jarno Basellini ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Protein Aggregates ◽  
Atypical Parkinsonisms

scholarly journals Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers

2017 ◽  
Vol 32 (2) ◽  
pp. 181-192 ◽  
Author(s):  
Antonio P. Strafella ◽  
Nicolaas I. Bohnen ◽  
Joel S. Perlmutter ◽  
David Eidelberg ◽  
Nicola Pavese ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Molecular Imaging ◽  
Atypical Parkinsonisms

scholarly journals Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms

BMC Neurology ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Anna Santaella ◽  
H. Bea Kuiperij ◽  
Anouke van Rumund ◽  
Rianne A. J. Esselink ◽  
Alain J. van Gool ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Biomarker Discovery ◽  
Atypical Parkinsonisms

scholarly journals Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms

2019 ◽  
Author(s):  
Anna Santaella ◽  
H. Bea Kuiperij ◽  
Anouke van Rumund ◽  
Rianne A.J. Esselink ◽  
Alain J. van Gool ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Growth Factor ◽  
Biomarker Discovery ◽  
Response To Treatment ◽  
Csf Biomarkers ◽  
Vascular Parkinsonism ◽  
Epidermal Growth ◽  
Atypical Parkinsonisms ◽  
Proximity Extension Assay

Abstract Background: Parkinson’s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression. Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed. Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01). Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.

scholarly journals Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms

2019 ◽  
Author(s):  
Anna Santaella ◽  
H. Bea Kuiperij ◽  
Anouke van Rumund ◽  
Rianne A.J. Esselink ◽  
Alain J. van Gool ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Growth Factor ◽  
Biomarker Discovery ◽  
Response To Treatment ◽  
Csf Biomarkers ◽  
Vascular Parkinsonism ◽  
Epidermal Growth ◽  
Atypical Parkinsonisms ◽  
Proximity Extension Assay

Abstract Background: Parkinson’s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression. Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed. Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01). Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.

scholarly journals Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms

2020 ◽  
Author(s):  
Anna Santaella ◽  
H. Bea Kuiperij ◽  
Anouke van Rumund ◽  
Rianne A.J. Esselink ◽  
Alain J. van Gool ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Growth Factor ◽  
Biomarker Discovery ◽  
Response To Treatment ◽  
Csf Biomarkers ◽  
Vascular Parkinsonism ◽  
Epidermal Growth ◽  
Atypical Parkinsonisms ◽  
Proximity Extension Assay

Abstract Background: Parkinson’s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression. Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed. Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01). Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.

Sign in / Sign up

Export Citation Format

Share Document